Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
Open Access
- 4 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (6) , 6752-6762
Abstract
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trialKeywords
This publication has 47 references indexed in Scilit:
- YKL-40 acts as an angiogenic factor to promote tumor angiogenesisFrontiers in Physiology, 2013
- YKL-40 Is Differentially Expressed in Human Embryonic Stem Cells and in Cell Progeny of the Three Germ LayersJournal of Histochemistry & Cytochemistry, 2011
- Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasNeuro-Oncology, 2011
- A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in CancersMolecular Cancer Therapeutics, 2011
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of GlioblastomaJournal of Biological Chemistry, 2011
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabNeuro-Oncology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- A multigene predictor of outcome in glioblastomaNeuro-Oncology, 2009
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesisOncogene, 2009
- Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profileMolecular Cancer, 2008